Aftertrade Broking Pvt Ltd ("Manager to the Offer") has submitted to BSE a copy of Recommendation of the Independent Director Committee ('IDC') in relation to the Open Offer ('Offer') to ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.2 pts less than Nifty Microcap 250 and 4.3 pts less than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The Independent Director Committee (IDC) of Aspira Pathlab & Diagnostics has submitted its recommendation to BSE on an Open Offer made by a group of five acquirers — Arvind Karsandas Bhanushali, Deepali Arvind Bhanushali, Jay Arvind Bhanushali, Nikunj Velji Mange, and Raj Arvind Bhanushali — along with one person acting in concert (Shraddha Nikunj Mange). The offer is for the acquisition of up to 26,76,180 equity shares (26% of paid-up capital) at Rs. 55 per share in cash, triggered under SEBI Takeover Regulations 3(1). Aftertrade Broking Pvt Ltd is the manager to the offer. The IDC reviewed the Public Announcement, Detailed Public Statement, Draft Letter of Offer, and Letter of Offer, and concluded that the offer price is fair and reasonable and in line with SEBI norms, with the shares classified as not frequently traded on BSE.
Shareholders can tender their shares at Rs. 55 per share in cash if they wish to exit. The IDC's positive recommendation signals the offer price meets SEBI's prescribed parameters, though the open offer window and tendering process details will follow. For the stock, this provides a clear price floor reference at Rs. 55 during the offer period.